Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
XEOMIN was licensed by Health Canada for adult patients with sialorrhea on the basis of a Phase III, randomized, double-blind, placebo-controlled, multicenter trial in which 184 patients participated.
Lead Product(s): Propofol
Therapeutic Area: Neurology Product Name: Diprivan
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 13, 2020
Premier through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.